Today in the spotlight โจ Janssen: Collaboration for a healthy future โจ Michel van Agthoven | Head Janssen/Johnson & Johnson Campus The Netherlands: โ๐๐ฉ๐ฆ ๐๐ถ๐ต๐ค๐ฉ ๐๐ช๐ง๐ฆ ๐๐ค๐ช๐ฆ๐ฏ๐ค๐ฆ & ๐๐ฆ๐ข๐ญ๐ต๐ฉ ๐ฆ๐ค๐ฐ๐ด๐บ๐ด๐ต๐ฆ๐ฎ ๐ช๐ด ๐ข๐ต๐ต๐ณ๐ข๐ค๐ต๐ช๐ท๐ฆ, ๐ฃ๐ฆ๐ค๐ข๐ถ๐ด๐ฆ ๐ฐ๐ง ๐ต๐ฉ๐ฆ ๐ฑ๐ณ๐ฆ๐ด๐ฆ๐ฏ๐ค๐ฆ ๐ฐ๐ง ๐ฉ๐ช๐จ๐ฉ๐ญ๐บ ๐ฆ๐ฅ๐ถ๐ค๐ข๐ต๐ฆ๐ฅ ๐ต๐ข๐ญ๐ฆ๐ฏ๐ต, ๐ต๐ฐ๐ฑ ๐ด๐ค๐ช๐ฆ๐ฏ๐ค๐ฆ ๐ข๐ฏ๐ฅ ๐ข ๐ท๐ช๐ฃ๐ณ๐ข๐ฏ๐ต ๐ฃ๐ช๐ฐ๐ต๐ฆ๐ค๐ฉ ๐ด๐ต๐ข๐ณ๐ต-๐ถ๐ฑ ๐ค๐ฐ๐ฎ๐ฎ๐ถ๐ฏ๐ช๐ต๐บ - ๐ข๐ญ๐ญ ๐ค๐ญ๐ฐ๐ด๐ฆ ๐ต๐ฐ ๐ฆ๐ข๐ค๐ฉ๐ฐ๐ต๐ฉ๐ฆ๐ณ. ๐๐ฉ๐ช๐ด ๐ฑ๐ณ๐ฐ๐ท๐ช๐ฅ๐ฆ๐ด ๐ข๐ฎ๐ฑ๐ญ๐ฆ ๐ฐ๐ฑ๐ฑ๐ฐ๐ณ๐ต๐ถ๐ฏ๐ช๐ต๐ช๐ฆ๐ด ๐ง๐ฐ๐ณ ๐ค๐ณ๐ฐ๐ด๐ด-๐ง๐ฆ๐ณ๐ต๐ช๐ญ๐ช๐ป๐ข๐ต๐ช๐ฐ๐ฏ ๐ข๐ฏ๐ฅ ๐ช๐ฏ๐ฏ๐ฐ๐ท๐ข๐ต๐ช๐ฐ๐ฏ. ๐๐ฆ ๐ข๐ณ๐ฆ ๐ค๐ฐ๐ฎ๐ฎ๐ช๐ต๐ต๐ฆ๐ฅ ๐ต๐ฐ ๐ง๐ถ๐ฆ๐ญ ๐ต๐ฉ๐ช๐ด ๐ฆ๐ค๐ฐ๐ด๐บ๐ด๐ต๐ฆ๐ฎ ๐ต๐ฉ๐ณ๐ฐ๐ถ๐จ๐ฉ ๐ฐ๐ถ๐ณ ๐ฑ๐ข๐ณ๐ต๐ฏ๐ฆ๐ณ๐ด๐ฉ๐ช๐ฑ๐ด ๐ธ๐ช๐ต๐ฉ ๐ฉ๐ฐ๐ด๐ฑ๐ช๐ต๐ข๐ญ๐ด, ๐ถ๐ฏ๐ช๐ท๐ฆ๐ณ๐ด๐ช๐ต๐ช๐ฆ๐ด, ๐ข๐ฏ๐ฅ ๐ณ๐ฆ๐ด๐ฆ๐ข๐ณ๐ค๐ฉ ๐ช๐ฏ๐ด๐ต๐ช๐ต๐ถ๐ต๐ฆ๐ด ๐ด๐ถ๐ค๐ฉ ๐ข๐ด ๐๐๐, ๐๐ข๐ฅ๐ฃ๐ฐ๐ถ๐ฅ ๐๐ฏ๐ช๐ท๐ฆ๐ณ๐ด๐ช๐ต๐บ ๐ข๐ฏ๐ฅ ๐๐ข๐ฅ๐ฃ๐ฐ๐ถ๐ฅ ๐๐๐, ๐๐ฏ๐ช๐ท๐ฆ๐ณ๐ด๐ช๐ต๐บ ๐ฐ๐ง ๐๐ฆ๐ช๐ฅ๐ฆ๐ฏ ๐ข๐ฏ๐ฅ ๐๐๐๐. ๐๐ฆ ๐ง๐ช๐ณ๐ฎ๐ญ๐บ ๐ฃ๐ฆ๐ญ๐ช๐ฆ๐ท๐ฆ ๐ต๐ฉ๐ข๐ต ๐ฃ๐บ ๐ค๐ฐ๐ญ๐ญ๐ข๐ฃ๐ฐ๐ณ๐ข๐ต๐ช๐ฐ๐ฏ, ๐ธ๐ฆโ๐ณ๐ฆ ๐ค๐ณ๐ฆ๐ข๐ต๐ช๐ฏ๐จ ๐ข ๐ง๐ถ๐ต๐ถ๐ณ๐ฆ ๐ธ๐ฉ๐ฆ๐ณ๐ฆ ๐ฅ๐ช๐ด๐ฆ๐ข๐ด๐ฆ ๐ช๐ด ๐ข ๐ต๐ฉ๐ช๐ฏ๐จ ๐ฐ๐ง ๐ต๐ฉ๐ฆ ๐ฑ๐ข๐ด๐ต.โ Janssen is one of the showcase companies in our bidbook 'Welcome to the Netherlands: Europe's Connected Life Sciences & Health Metropolis'. Together, as pharmaceutical company of Johnson & Johnson, Janssen regards end-to-end activities for medicines and vaccines from lab to patient. This covers research & development at Janssen Vaccines & Prevention, manufacturing at Janssen Biologics, and distribution and marketing at Janssen the Netherlands. Want to read more about Janssen and other companies located in The Netherlands? Have a look in our bidbook and find out why the Netherlands is an attractive place for innovative business: https://lnkd.in/eQYeTd8J TNO Radboud University Radboudumc Universiteit Leiden Leiden University Medical Center The Janssen Pharmaceutical Companies of Johnson & Johnson Janssen Europe, Middle East & Africa (EMEA)
Health~Holland Internationalโs Post
More Relevant Posts
-
Healthcare is entering a defining moment, with an opportunity to embrace a new wave of innovation. Yet if Europe is to realise the full potential of these breakthroughs, it is vital that people across the region have more timely and equitable access to these treatments. ย It is with this potential in mind that I take up a new position on the Board of the European Federation of Pharmaceutical Industries and Associations (EFPIA) โ the main body representing the research-based biopharmaceutical industry in Europe. ย Alongside my peers from world-leading pharmaceutical companies, I will be working to help deliver on EFPIAโs mission to create an environment that enables our industry to innovate, thrive and deliver new therapies across Europe. At Pfizer, our goal is to change the lives of one billion patients a year by 2027 โ but as EFPIAโs mission alludes, this is only possible with the right policy and legislative environment in place. ย Europe is often seen as a pharmaceutical powerhouse, with the skilled workforce, academic infrastructure, multi-national institutions, and manufacturing capability making it a location of choice for life science investment. Yet in spite of all this expertise and promise there is still significant inequity in access to new medicines. Patients in Europe are having to wait 517 days for access to innovative treatments on average, ranging from 128 days up to a staggering 1,351 days.* This is an unacceptable situation, and I believe our industry is and should remain an important voice in profiling and remedying this issue. Timely and equitable access is a cause I am deeply passionate about. Through my new role on the EFPIA Board, I am committed to finding and fighting for solutions in partnership with policymakers and stakeholders across Europe, based on a shared understanding of the root causes of unavailability and access delays. This is a real opportunity to create a modernised system that can embrace the next generation of medicines and vaccines. Together, I hope we can achieve a healthier and stronger Europe. * https://lnkd.in/egnbJgvd ย #EFPIAย #HealthPolicy #LifeSciences #HealthofEurope #MedicineAccess ย
To view or add a comment, sign in
-
Global Public Affairs and Communications Leader | Meaningful Partnerships Builder | Learner and Teacher
Congratulations Michael Boyd! You'll be great in this, and I couldn't agree with you more. On that note, here's the link to a nice ebook (just published by the incredible Jill Donahue, Fueling the power of purpose in pharma teams), which tells the stories of 100 pharma leaders, a tool perhaps to leverage in telling a piece of our story: A Dose of Inspiration: 100 Purpose Stories from Pharma Leaders (https://lnkd.in/efCEvCX8)
Iย amย delighted toย announce that Iย have been appointed as the new Chair of the International Federation of Pharmaceutical Manufacturers and Associations (IFPMA) Council.ย This is in addition to continuing in my role leading Government Affairs at Gilead. IFPMA is the global industry association, and represents innovative biopharmaceutical companies and associations from around the world. For over 50 years, IFPMA has been a bridge between the innovative pharmaceutical industry and other stakeholders in the global health community. It works closely with all public health stakeholders in the UN system, including the World Health Organization, World Trade Organization and the World Intellectual Property Organization. It also partners with governments, global health organizations, NGOs, civil society, patient groups, research and academic institutions and others. ย IFPMAย is close to my heart, having led the organization asย the Interimย Director General in 2009 and served on a wide range of committees and working groups over the course of my career, most recently as Chair of the Global Health and Access Committee. ย Itย isย more importantย than everย for us to tell the story of how our industry discovers and develops new medicines and vaccines and makes them available to patients. IFPMA has achieved aย number of notable achievementsย under the leadership ofย Director General Thomas Cueniย and Council Chair Amadou Diarraย (pictured), and I would like to thank them for their tireless dedication and commitment. ย In the months and years to come,ย I look forward to working closely with incoming Director Generalย David Reddy and the IFPMA Team to build on their success, inspiring the global health community about the innovation our industry brings toย patients, and ensuring fruitful collaborations to improve access and health outcomes everywhere. ย
To view or add a comment, sign in
-
๐ Whatโs stopping pharma companies from running commercial trials in Africa? We agree it's the right and ethical thing to do, yet it isn't happening... No one wants to be the first. eMQT proposes a change! ๐ Calling all pharma companies committed to diversity in clinical trials. Join us in building Centres of Excellence together! ๐ Hereโs our simple 3-step proposal: 1๏ธโฃ Meet with eMQT to discuss your therapeutic area and patient population focus. 2๏ธโฃ We identify suitable sites and countries in Africa to match your needs. 3๏ธโฃ Collaborate with us to build Centres of Excellence! Letโs lead the way in transforming clinical research.๐ก๐ค #DiversityInTrials #ClinicalResearch #PharmaInnovation Contact us today to start the journey! ๐ https://buff.ly/40eOKUb Pfizer Roche AstraZeneca Gilead Sciences Vertex Pharmaceuticals Veramed Takeda GSK Genentech Novartis Moderna Shalom Ijeoma Lloyd MBE Tina Barton Emily Moore Hannah White Nancy Meyerson-Hess
To view or add a comment, sign in
-
๐ฌ Catalonia has become a top destination worldwide and in Europe for the development of clinical trials. ๐งช 5,308 clinical trials currently underway. ๐ No. 8โฃ in the world & No. 5โฃ in Europe. ๐ 88.5% of Spain's clinical trials are conducted in the #BioRegionCatalonia. Catalonia particularly excels in #oncology trials, which represent 34% of the total, followed by other therapeutic areas such as the immune system and the respiratory system. The quality of the #health system has attracted top #pharma multinationals such as Novartis, Roche, Bristol Myers Squibb, AstraZeneca, Pfizer, GSK, Sanofi, Eli Lilly and Company, The Janssen Pharmaceutical Companies of Johnson & Johnson, MSD, or AbbVie to Catalonia to develop their trials. ๐ Check the data in the #BioRegionReport 2023: https://report.biocat.cat/ Promoted by: Biocat, BioRegion of Catalonia With the support of: Amgen, Almirall, AstraZeneca, Cuatrecasas, ESTEVE, and Sanofi. In collaboration with: CataloniaBio & HealthTech, ACCIร, Farmaindustria, and Fenin, Federaciรณn Espaรฑola de Empresas de Tecnologรญa Sanitaria.
To view or add a comment, sign in
-
GSK to infuse ยฃ200M into UK manufacturing, pharma API In a strategic move to fortify its manufacturing capabilities, GlaxoSmithKline (GSK) is demonstrating a steadfast commitment to the United Kingdom, announcing an investment exceeding ยฃ200 million ($253 million) by 2025. The pharmaceutical giant is channeling substantial resources into enhancing its U.K. supply network, encompassing the construction of new facilities and the development of innovative assembly lines. A pivotal aspect of this initiative is the ongoing ยฃ67 million ($85 million) upgrade to GSK's manufacturing site in Montrose, Scotland. Scheduled for completion this year, the upgraded facility will play a crucial role in producing active pharmaceutical ingredients (API) to support the future supply of medicines. Furthermore, GSK is set to commence operations at its ยฃ65 million ($82 million) site in Ware, England, which commenced operations in September. This global manufacturing hub for GSK will be pivotal in manufacturing some of the company's most "commercially important" medicines, including those addressing HIV. GSK's commitment to the U.K. is underscored by its investment in six manufacturing sites across the country. This strategic move stands in contrast to some industry peers, such as AstraZeneca, which opted for international expansion, citing concerns about the U.K.'s tax policies. Notably, GSK is not limiting its investments to the U.K., recently pledging 250 million euros ($273 million) for a state-of-the-art facility at its Wavre campus in Belgium, supporting the company's burgeoning vaccine ambitions, including the launch of its RSV shot, Arexvy. As GSK forges ahead with these strategic investments, it solidifies its position as a key player in the global pharmaceutical landscape. #api #pharmamanufacturing #biotech #bigpharma #sanofi #gsk #pfizer #sunpharma #cipla #lupin #drreddys #pharmamarketing #pharmacompanies
To view or add a comment, sign in
-
Sanofi's Strategic Move: Spinning Off Consumer Healthcare Division Valued at โฌ20 Billion Sanofi is embarking on a significant strategic shift by spinning off its consumer healthcare division, a move that is anticipated to be valued at approximately โฌ20 billion. Notably, this decision has been facilitated by reputable financial institutions such as Goldman Sachs and Morgan Stanley, aligning with a prevailing trend in the pharmaceutical industry. This trend involves the segregation of lower-margin consumer units from higher-margin pharmaceutical segments. CEO Paul Hudson is driving the company towards concentrating on research and development (R\&D) for rare diseases and immunology, despite a transient decline in Sanofi's shares following the announcement. The spin-off process is set to adopt a "dual track" approach, encompassing both a potential sale and a public listing, in a bid to optimize the expected outcomes. This strategic realignment is geared towards streamlining Sanofi's operations and intensifying its focus on innovative medicine. This move mirrors recent strategic endeavors by major players in the industry, such as GSK and Johnson & Johnson. # Thank you Fabienne Durand for your submission!
To view or add a comment, sign in
-
๐ข We want to identify top companies with ready-for-market products in the biopharmaceutical industry and look for experts to conduct that analysis
๐ #CallforProposals 83470023, closing 20 September 2024: To conduct the landscape assessment of the Biopharmaceutical Industry in South Africa Theย SAVax - "Vaccines for Africa - Rollout and Production in South Africa (SAVax)"ย projectย seeks a contractor to conduct a landscape assessment of South Africa's biopharmaceutical industry. South African companies face challenges in market intelligence, demand forecasting, high production costs, and complex technology transfers. These obstacles hinder their ability to establish local manufacturing capacities for vaccines, medicines, and health technologies. The assessment will identify companies with "ready-for-market" products that could potentially benefit from targeted technical assistance to enhance their manufacturing capacity and better meet market opportunities at national, regional, and continental levels. GIZ invites eligible and professional companies with local presence in South Africa, to participate in this tender. ๐Tender Documents are available for downloading here https://lnkd.in/da9FZqKy Completed forms must be submitted toย [email protected]. Please quote referenceย 83470023ย when submitting the documentation. Late submissions will not be accepted. ๐ Theย Deutsche Gesellschaft fรผr Internationale Zusammenarbeit (GIZ) SAVaxย project on behalf of theย German Federal Ministry for Economic Cooperation and Development (BMZ)ย and theย European Union, together with theย Department of Science and Innovation (DSI)ย andย National Department of Health (DoH), launches a tender to conduct a landscape assessment of the Biopharmaceutical Industry in South Africa. Theย SAVax - "Vaccines for Africa - Rollout and Production in South Africa (SAVax)"ย project aims to provide improved access to high-quality vaccines for all people living in South Africa. It has two components: supporting vaccine roll-out and boosting local vaccine production in South Africa for the African continent. Specifically, the project aims to enhance the enabling environment for local pharmaceutical and health technology production through research, development, and skills training, to strengthen the regulatory framework, and to support the demand and supply of locally produced health goods. This initiative is part of theย Team Europe Initiativeย onย Manufacturing and Access to Vaccines, Medicines and Health Technologies in Africa (TEI MAV+). #BiopharmaceuticalIndustryAssessment #VaccineProduction #LocalManufacturing #HealthInnovation #BiopharmaLandscape #SAHealthcare
To view or add a comment, sign in
-
๐ Greece shines on the global stage as the host of the prestigious Biopharmaceutical CEO Roundtable! For two days, Athens becomes the epicenter of the pharmaceutical world, welcoming the CEOs of the largest pharmaceutical companies globally. This elite gathering, orchestrated by the IFPMA International Federation of Pharmaceutical Industries and Associations every two years, underscores Greece's burgeoning appeal as a magnet for healthcare investment. Prime Minister Kyriakos Mitsotakis will engage with the titans of the top 20 pharma companies during a closed working lunch today. The discussions will continue tomorrow focusing on pivotal issues like innovative treatments, market access, and regulatory frameworks. These conversations are not just about policy but signal Greece's strategic position in the global healthcare ecosystem. With the participation of pharmaceutical leaders such as Pfizer Boehringer Ingelheim Bristol Myers Squibb Johnson & Johnson, Novo Nordisk, Sanofi , Eli Lilly and Company, Takeda, MENARINI Group, Bayer | Pharmaceuticals, and others, the spotlight is on Greece. The event is expected to catalyze new investments. Greece is not just a beautiful destination but a thriving hub for pharmaceutical innovation and investment. Enterprise Greece SA #PharmaInGreece2024 #HealthcareInnovation #InvestInGreece
To view or add a comment, sign in
1,679 followers